Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 20/20 | 0.87 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20176384 | 0.97 | ELANE (0.82) | ELANECYP2C9CYP3A4ADRB1HTR1A | |
| SCHEMBL13872877 | 0.95 | ELANE (0.86) | ELANECYP2C9CYP3A4ADRB1HTR1A | |
| SCHEMBL3707890 | 0.93 | ELANE (1.00) | ELANECYP2C9CYP3A4ADRB1HTR1A | |
| SCHEMBL2894380 | 0.93 | ELANE (1.00) | ELANECYP2C9CYP3A4ADRB1HTR1A | |
| SCHEMBL13872095 | 0.93 | ELANE (0.87) | ELANECYP2C9CYP3A4ADRB1HTR1A | |
| SCHEMBL14899925 | 0.93 | ELANE (0.89) | ELANECYP2C9CYP3A4ADRB1HTR1A | |
| SCHEMBL8345574 | 0.93 | ELANE (0.81) | ELANECYP2C9CYP3A4ADRB1HTR1A | |
| SCHEMBL2894512 | 0.92 | ELANE (0.86) | ELANECYP2C9CYP3A4ADRB1HTR1A | |
| SCHEMBL392232 | 0.92 | ELANE (1.00) | ELANECYP2C9CYP3A4ADRB1HTR1A | |
| SCHEMBL3482731 | 0.92 | ELANE (1.00) | ELANECYP2C9CYP3A4ADRB1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10201536-B2 | Methods and pharmaceutical compositions for the treatment of bacterial infections in patients suffering from cirrhosis | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2019-02-12 | — | — | US | disclosed |
| US-20180140597-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS IN PATIENTS SUFFERING FROM CIRRHOSIS | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2018-05-24 | — | — | US | disclosed |
| WO-2014186623-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF A CHAGAS DISEASE | BIOMED VALLEY DISCOVERIES (US) | 2014-11-20 | — | — | WO | disclosed |
| US-20090105268-A1 | Dihydropyrimidone Multimers and Their Use as Human Neutrophil, Elastase Inhibitors | ARGENTA DISCOVERY LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
| US-20090105268-A1 | Dihydropyrimidone Multimers and Their Use as Human Neutrophil, Elastase Inhibitors | ARGENTA DISCOVERY LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
| WO-2006136857-A1 | DIHYDROPYRIMIDONE MULTIMERS AND THEIR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | ARGENTA DISCOVERY LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10201536-B2 | Methods and pharmaceutical compositions for the treatment of bacterial infections in patients suffering from cirrhosis | TLR8, TLR7, TLR3 | ELANE 99/4885CYP2C9 4290/4885CYP3A4 3972/4885 |
| US-20180140597-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS IN PATIENTS SUFFERING FROM CIRRHOSIS | TLR8, TLR7, TLR3 | ELANE 99/4885CYP2C9 4290/4885CYP3A4 3972/4885 |
| US-20090105268-A1 | Dihydropyrimidone Multimers and Their Use as Human Neutrophil, Elastase Inhibitors | SERPINB1, ELANE, MPO | ELANE 2/4885CYP2C9 3835/4885CYP3A4 2182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.